Metraipolis › archive › dc_e673a455249e
Cost-effectiveness analysis of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for extensive-stage small cell lung… — Europe PMC PMID:41164828
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41164828
- DOI
- 10.3389/fpubh.2025.1652917
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-09T07:36:29.530Z
- SHA-256 of the archived text
31dc452ca863b06fcbd5e80eb3265e219c6ce9812951ea822ddc5be39d9cdb21- Stable URL of this page
https://metraipolis.com/documento/dc_e673a455249e
How to cite
Cost-effectiveness analysis of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for extensive-stage small cell lung… — Europe PMC PMID:41164828 — Europe PMC (en), https://europepmc.org/article/MED/41164828 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_e673a455249e (Metraipolis archive dc_e673a455249e, sha256 31dc452ca863b06fcbd5e80eb3265e219c6ce9812951ea822ddc5be39d9cdb21)
BibTeX
@misc{dce673a455249e,
title = {Cost-effectiveness analysis of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for extensive-stage small cell lung… — Europe PMC PMID:41164828},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41164828},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_e673a455249e; sha256 31dc452ca863b06fcbd5e80eb3265e219c6ce9812951ea822ddc5be39d9cdb21},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41164828. Agents can read the archived copy with the MCP tool read_document.